 |
34 Diseases |  |
9 Trials |
|
9 Trials |  |
673 News |  |
| «12345678 |
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P1 trial: Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA (clinicaltrials.gov) - Sep 19, 2012
P1, N=25, Completed, Sponsor: Sanofi
- efavirenz / Generic mfg.
Enrollment closed: Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) (clinicaltrials.gov) - Aug 30, 2012
P4, N=90, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting
- Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P3 trial: Efavirenz to Rilpivirine FDC Switch Study (EUDRACT) - Aug 2, 2012
P3, N=40, Ongoing, Sponsor: St Stephen's AIDS Trust
- Isentress (raltegravir) / Merck (MSD)
Enrollment open: Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated (clinicaltrials.gov) - Jun 11, 2012
P4, N=48, Recruiting, Sponsor: Hospital Clinic of Barcelona
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Pegasys (pegylated interferon ? -2a) / Roche, Isentress (raltegravir) / Merck (MSD)
New P1/2 trial: Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. (clinicaltrials.gov) - Mar 27, 2012
P1/2, N=52, Completed, Sponsor: Gilead Sciences
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment open: Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=22000, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial withdrawal: Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial (clinicaltrials.gov) - Feb 13, 2012
P3, N=0, Withdrawn, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Not yet recruiting --> Recruiting Suspended --> Withdrawn
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial (clinicaltrials.gov) - Feb 13, 2012
P3, N=0, Withdrawn, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Suspended --> Withdrawn N=960 --> 0
- | Trial completion: Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) (clinicaltrials.gov) - Feb 13, 2012
P3, N=120, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
N=960 --> 0 Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
New P4 trial: Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated (clinicaltrials.gov) - Feb 7, 2012
P4, N=48, Recruiting, Sponsor: Hospital Clinic of Barcelona
- Trial initiation date: REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment (clinicaltrials.gov) - Jan 24, 2012
P4, N=836, Recruiting, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Oct 2011
- Enrollment open: REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment (clinicaltrials.gov) - Jan 24, 2012
P4, N=836, Recruiting, Sponsor: AIDS Clinical Trials Group
Initiation date: Jul 2011 --> Oct 2011 Not yet recruiting --> Recruiting
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., pravastatin / Generic mfg.
New P2 trial: Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation (clinicaltrials.gov) - Jan 22, 2012
P2, N=225, Suspended, Sponsor: AIDS Clinical Trials Group
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., etoposide IV / Generic mfg.
Trial initiation date: REACT-KS: Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma (clinicaltrials.gov) - Jan 18, 2012
P3, N=468, Recruiting, Sponsor: AIDS Clinical Trials Group
Not yet recruiting --> Recruiting Initiation date: Jun 2011 --> Oct 2011
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., etoposide IV / Generic mfg.
Enrollment open: REACT-KS: Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma (clinicaltrials.gov) - Jan 18, 2012
P3, N=468, Recruiting, Sponsor: AIDS Clinical Trials Group
Initiation date: Jun 2011 --> Oct 2011 Not yet recruiting --> Recruiting
- | emtricitabine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed, Monotherapy: DREAM: Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients (clinicaltrials.gov) - Dec 8, 2011
P2/3, N=420, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla (clinicaltrials.gov) - Nov 17, 2011
P4, N=115, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Trial withdrawal: Raltegravir Activity In Lymphoid Tissues (clinicaltrials.gov) - Oct 24, 2011
P=N/A, N=10, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- || New P3 trial, IO biomarker, Metastases: Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (clinicaltrials.gov) - Sep 13, 2011
P3, N=706, Recruiting, Sponsor: AIDS Clinical Trials Group